Invention Publication
- Patent Title: T CELL ACTIVATING IMMUNOTHERAPEUTIC FOR TREATMENT OF MUCIN 1 PROTEIN EXPRESSING HUMAN CANCERS
-
Application No.: US18381979Application Date: 2023-10-19
-
Publication No.: US20240317828A1Publication Date: 2024-09-26
- Inventor: Frank Bedu-Addo , Joseph Dervan , Gregory Conn
- Applicant: PDS BIOTECHNOLOGY CORPORATION
- Applicant Address: US NJ Princeton
- Assignee: PDS BIOTECHNOLOGY CORPORATION
- Current Assignee: PDS BIOTECHNOLOGY CORPORATION
- Current Assignee Address: US NJ Princeton
- Main IPC: C07K14/47
- IPC: C07K14/47 ; A61K38/00 ; A61K39/00

Abstract:
Provided herein are multiepitope peptides including at least one mucin 1 (MUC1) peptide, the multiepitope peptides have MHC affinity for at least one of HLA serotype and are recognized by a CD4+ T cell receptor and/or by a CD8+ T cell receptor. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various aspects, the cationic lipid is R-DOTAP. The invention also provides methods of use of the multiepitope peptides and of the compositions and vaccine compositions. The methods of use include methods of treating cancer and method of inducing a MUC-specific polyfunctional cytolytic T cell response in a subject.
Information query